Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

AIM: Selexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy with endothelial receptor antagonists (ERAs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Xiaopei, Lu, Weida, Zhang, Deyuan, Qie, Liangyi, Li, Haijun, Li, Xiao, Liu, Hui, Ji, Qiushang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530145/
https://www.ncbi.nlm.nih.gov/pubmed/36204579
http://dx.doi.org/10.3389/fcvm.2022.991586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530145/
https://www.ncbi.nlm.nih.gov/pubmed/36204579
http://dx.doi.org/10.3389/fcvm.2022.991586

Ejemplares similares